Big Pharma Opens $1.5 Trillion "War Chest"

Biotech buyouts spell a massive profit opportunity

 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Biotech buyouts spell a massive profit opportunity

                                                                                                     

Outsider Club's VIP Reserve: Outsider Club's VIP Reserve

PAID SUBSCRIBERS ONLY June 27, 2023 Big Pharma is hunting for the best new treatments for rare diseases. And with a $1.5 trillion war chest of cash at their disposal, these giants are quickly gobbling up the small biotech firms that are developing them... Creating a tsunami of profits for early investors. Take Merck, for instance, the $291 BILLION biotech powerhouse. Merck just bought out Prometheus Biosciences for $10.8 billion to acquire its cutting-edge autoimmune disease treatments. This announcement propelled Prometheus' stock 70% higher in just THREE days! And this is hardly an isolated example. Big Pharma buyouts are causing several small biotech firms to skyrocket in a short time: Amgen agreed to acquire Horizon Therapeutics PLC for $27.8 billion, sending Horizon's stock up 78% in two months. Johnson & Johnson struck a $16.6 billion deal to acquire Abiomed, causing the stock to jump 50% in only two days. Pfizer just bought Global Blood Therapeutics for $5.4 billion, whose stock jumped 45% in two days. But this is only the beginning... Because we are witnessing the "Industrial Revolution" in biotech. The massive wave of innovation occurring throughout the sector is the dawn of a Golden Age. Lifesaving medicines and treatments could get to patients much faster — and much more cheaply. We could even witness the cure for cancer... or even the cure for ALL diseases. And with Big Pharma flexing its huge trillion-dollar war chest of cash, scooping up these tiny firms left and right... Biotech is going to be THE hottest place for investors to be in 2023. The best part is that ANYONE can invest in these small biotech stocks. And you don't need to be a doctor, a biochemist, or even have a college degree. You just need to know which stocks to buy, when to buy them, and when to sell them. And I can show you EXACTLY how to do that with my proprietary Project Greenlight trading strategy. With this strategy, you can predict down to the VERY day when a biotech stock is likely to explode... With signals showing as much as 95% confidence... Giving you a shot at FOUR triple-digit winners every single month! For instance, my readers have already seen gains like: 3,278% on Aquinox Pharmaceuticals 190% on ProQR Therapeutics 212% on Prana Biotechnology 54% on Dova Pharmaceuticals 86% on Aldeyra Therapeutics 87.3% on Viking Therapeutics 113.3% on Editas Medicine 669% on Amarin Corporation And that's just to name a few. Now, remember, these are fast-moving gains... Which is why I urge you to act as quickly as possible. We're talking about more new innovations, drugs, and therapies than ever before... That could set you up to potentially clock massive paydays of 212%, 669%, and even 3,278%... From the most lucrative and fast-paying biotech stocks in the world. And I'm not talking about multibillion-dollar giants like Pfizer, Johnson & Johnson, or Merck... But rather the smaller, innovative companies that are not covered by the mainstream press... The billion-dollar buyout targets for these massive, cash-rich pharmaceutical giants. Take advantage of this now. To your wealth, Keith Kohl Investment Director, Topline Trader

---

This email was sent to indra21poetra@gmail.com. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may unsubscribe here, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Outsider Club's VIP Reserve, please add customerservice@outsiderclub.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. Outsider Club VIP Reserve, Copyright © 2023, Outsider Club LLC. All rights reserved. 3 E Read Street Baltimore, MD 21202. For customer service, call (855) 496-0830. The content of this site may not be redistributed without the express written consent of the Outsider Club. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and the Outsider Club as well as a link to www.outsiderclub.com. Your privacy is important to us. We will never rent or sell your e-mail or personal information. Please read our Privacy Policy. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Outsider Club does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. All Investments in Stocks, Options, Bonds, ETFs and Futures may carry a significant risk of loss.